Vega GLG, Hernández CMK, Hernández ZSS

Language: Spanish
References: 20
Page: 394-396
PDF size: 151.31 Kb.

ABSTRACT

Latanoprost is a prostaglandin f2 analogue used for the treatment of glaucoma in order to decrease intraocular pressure, however some cases have been reported with improvement of depigmentation in eyelid vitiligo, and few side effects.
We report a 12-year-old female with eyelid vitiligo with multiple previous treatments without adequate response, but latanoprost showed important improvement after three months.

REFERENCES

1. Taieb A y Picardo M, The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force, Pigment Cell Res 2007; 20:27-35.

2. Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y et al., The prevalence of vitiligo: a meta-analysis, plos One 2016; 11(9): e0163806.

3. Dwivedi M, Laddha NC, Shajil EM, Shah BJ y Begum R, The ace gene i/d polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population, Pigment Cell Melanoma Res 2008; 21:407-8.

4. Kyriakis KP, Palamaras I, Tsele E, Michailides C y Terzoudi S, Case detection rates of vitiligo by gender and age, Int J Dermatol 2009; 48:328-9.

5. Tamer E, Ilhan MN, Polat M, Lenk N, Alli N, Prevalence of skin diseases among pediatric patients in Turkey, J Dermatol 2008; 35:413-8.

6. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ et al., Guideline for the diagnosis and management of vitiligo, Br J Dermatol 2008; 159:1051-76.

7. Alikhan A, Felsten LM, Daly M y Petronic-Rosic V, Vitiligo: a comprehensive overview. Part i. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up, J Am Acad Dermatol 2011; 65:473-91.

8. Speeckaert R y Van Geel N, Vitiligo: an update on pathophysiology and treatment options, American Journal of Clinical Dermatology 2017; 18(6):733-44.

9. Le Poole IC, Das PK, Van den Wijngaard RM, Bos JD y Westerhof W, Review of the etiopathomechanism of vitiligo: a convergence theory, Exp Dermatol 1993; 2:145-53.

10. Halder RM y Taliaferro SJ, Vitiligo. En Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A y Lefell D (eds.), Fitzpatrick’s dermatology in general medicine, Nueva York, McGraw-Hill, 2008, p. 72.

11. Taieb A, Alomar A, Böhm M, Dell’Anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, Van der Veen W, Van Geel N, Whitton M, Wolkerstorfer A y Picardo M, Guidelines for the management of vitiligo: the European Dermatology Forum consensus, British Association of Dermatologists 2013; 168:5-19.

12. Alm A, Latanoprost in the treatment of glaucoma, Clinical Ophthalmology (Auckland, Nueva Zelanda) 2014; 8:1967-85.

13. Dams I, Wasyluk J, Prost M y Kutner A, Therapeutic uses of prostaglandin f2α analogues in ocular disease and novel synthetic strategies, Prostaglandins & Other Lipid Mediators 2013; 104:109-21.

14. Russo A, Riva I, Pizzolante T, Noto F y Quaranta L, Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review, Clinical Ophthalmology 2008; 2(4):897.

15. Picardo M et al., Vitiligo, Nature Reviews 2015; 1:1-16.

16. Dell’Anna ML y Picardo MA, Review and a new hypothesis for nonimmunological pathogenetic mechanisms in vitiligo, Pigment Cell Res 2006; 5:406-11.

17. Anbar TS, El‐Ammawi TS, Abdel‐Rahman AT y Hanna MR, The effect of latanoprost on vitiligo: a preliminary comparative study, International Journal of Dermatology 2015; 54(5):587-93.

18. Kiumars N, Azita H, Ghasem R et al., Efficacy of topical latanoprost in the treatment of eyelid vitiligo: a randomized, double-blind clinical trial study, Dermatol Ther 2020; 33(1):e13175.

19. Korobko IV y Lomonosov KM, A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow‐band ultraviolet b phototherapy and microneedling for the treatment of nonsegmental vitiligo, Dermatologic Therapy 2016; 29(6):437-41.

20. Choi YM, Diehl J y Levins PC, Promising alternative clinical uses of prostaglandin f2α analogs: beyond the eyelashes, Journal of the American Academy of Dermatology 2015; 72(4):712-6.